VolitionRX Limited (VNRX)
VNRX trades on NYSE in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.1847
-9.06% on the day
Market cap
$5.6M
Nano cap
Revenue · 2025
$1.7M
+40.0% on 2024
Net income · 2025
-$23.4M
-1352.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | VNRX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | Singapore |
| IPO year | 2015 |
| SEC CIK | 0000093314 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.7M |
| Net income | -$23.4M |
| Operating income | -$21.7M |
| Net margin | -1352.2% |
| Operating margin | -1258.5% |
| Revenue growth | +40.0% |
| Cash | $1.1M |
| Total assets | $6.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2026-08-28 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-30 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-13 |
| Latest current report FORM 8-K | 8-K | 2026-09-25 |
| Latest proxy | DEF 14A | 2026-06-02 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc. | $1.75 | -1.69% | $5.2M |
| TRIB | Trinity Biotech plc | $6.30 | -3.96% | $5.1M |
| QCLS | Q/C Technologies Inc. | $0.5465 | -5.79% | $4.5M |
| BMRA | Biomerica Inc. | $1.85 | +0.82% | $8.5M |
| VRAX | Virax Biolabs Group Limited | $1.74 | -6.05% | $2.3M |
| IMDX | Insight Molecular Diagnostics Inc. | $2.99 | -5.68% | $97.8M |
| ICCC | ImmuCell Corporation | $10.79 | +12.40% | $98.0M |
| MYGN | Myriad Genetics Inc. | $4.08 | -2.86% | $390.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier